

DOCTORAL THESIS

A study on the anti-inflammatory activity and mechanism of action of herba siegesbeckiae (Xixiancao)

Guo, Hui

Date of Award:
2018

[Link to publication](#)

General rights

Copyright and intellectual property rights for the publications made accessible in HKBU Scholars are retained by the authors and/or other copyright owners. In addition to the restrictions prescribed by the Copyright Ordinance of Hong Kong, all users and readers must also observe the following terms of use:

- Users may download and print one copy of any publication from HKBU Scholars for the purpose of private study or research
- Users cannot further distribute the material or use it for any profit-making activity or commercial gain
- To share publications in HKBU Scholars with others, users are welcome to freely distribute the permanent URL assigned to the publication

ABSTRACT

Herba *Siegesbeckiae* (HS, *Xixiancao* in Chinese) is a commonly used traditional Chinese medicinal herb for treating inflammatory disorders such as arthritis and rheumatoid arthritis (RA). In ancient materia medica books, HS is recorded to be the aerial part of *Siegesbeckia pubescens* (SP) which is also the sole plant origin of HS in the 1963 edition of the Chinese Pharmacopeia (ChP). The aerial parts of *Siegesbeckia orientalis* (SO) and *Siegesbeckia glabrescens* (SG) have been included as two additional origins for HS in each edition of ChP since 1977. Likewise, the aerial parts of these three species are recorded as origins for HS in the Hong Kong Chinese Materia Medica Standards (HKCMMS). HS has been reported to exert anti-inflammatory effects by inhibiting the MAPKs and NF- κ B pathways that are the components of Toll-like receptor 4 (TLR4) signaling. Until now, no chemical or pharmacological comparison among the three *Siegesbeckia* herbs has been conducted to answer the question whether the three herbs could all be used as HS origins. The role of TLR4 in the anti-inflammatory effect of HS has not been determined yet. This study aims to determine whether the aerial parts of SP, SO and SG can all be used as HS, and to explore the involvement of the TLR4 pathways in HS's anti-arthritic action.

To determine whether the three *Siegesbeckia* plants can all serve as the origins of HS, we compared their fingerprint chromatograms and inhibitory effects on inflammatory mediators. Chemical analyses showed that the three species have different profiles, although they have common peaks in their fingerprint chromatograms. Hierarchical cluster analysis (HCA) and principal component analysis (PCA) of the common peaks demonstrated that all samples of the three species tend to be species-dependently grouped and separated. Ten components contributing to the species discrimination were identified, of which 8 are long-chain fatty acids/esters, and 2 are darutoside and hythiemoside A. Inhibitory effects of the three species on NO production and IL-6 secretion in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages are different, with SG being the most and SP the least potent. These chemical and bioactivity assays support the notion that the three *Siegesbeckia* species cannot be equally used as the plant origins of HS.

To investigate the involvement of TLR4 signaling in the anti-inflammatory effect of HS, we evaluated the anti-arthritic effects of an ethanolic extract of HS (HS for short, the dried aerial part of SO) in rats with collagen-induced arthritis (CIA), and investigated the involvement of TLR4 signaling in the effects of HS in

the CIA rats and RAW264.7 macrophages. Results showed that HS possesses anti-arthritic effects and has no observable adverse effects. *In vitro* and *in vivo* mechanistic studies reveal that HS's therapeutic effects is at least partially attributed to its inhibitory action on the IRAK4/MAPKs/AP-1, IRAK4/MAPKs/NF- κ B, IRAK4/PI3K/NF- κ B and TRAF3/TBK1/IRF3 pathways. We further found that HS inhibits LPS-TLR4 binding. To find out the compound responsible for inhibiting LPS-TLR4 binding, we first identified chemicals in HS by UHPLC/Q-TOF-MS analysis. Subsequent simulated computational and experimental studies showed that ursolic acid is one of the main active components. These studies demonstrated the anti-arthritic activity, the TLR4-signaling-related mechanism of action, and the active compound of HS.

This work provides a chemical and pharmacological basis for determining whether the three *Siegesbeckia* genus herbs SP, SO and SG can all serve as the origins of HS; and also provides pharmacological justifications for the clinical application of HS in treating inflammatory disorders.

TABLE OF CONTENTS

DECLARATION	i
ABSTRACT.....	ii
ACKNOWLEDGEMENTS	iv
TABLE OF CONTENTS.....	v
LIST OF TABLES	xi
LIST OF FIGURES	xii
LIST OF ABBREVIATIONS.....	xix
CHAPTER 1 INTRODUCTION	1
1.1 Rheumatoid arthritis (RA)	1
1.1.1 Pathophysiology of RA.....	1
1.1.2 TLR4 in RA	1
1.1.3 Pharmacologic therapies and side effect.....	6
1.2 Herba Siegesbeckiae (HS)	8
1.2.1 Traditional record	8
1.2.2 Morphological features	11
1.2.3 Chemical constituents	14
1.2.4 Pharmacological properties.....	25
1.3 Hypothesis	29
1.4 Objectives	29
CHAPTER 2 COMPARISON OF THE CHEMICAL PROFILES AND INFLAMMATORY MEDIATOR-INHIBITORY EFFECTS OF THREE <i>SIEGESBECKIA</i> HERBS USED AS HS.....	30
2.1 Abstract.....	30
2.2 Introduction.....	32
2.3 Materials and methods	32
2.3.1 Reagents and materials	32
2.3.2 Herbal preparation	34

2.3.3 HPLC analysis	41
2.3.4 UHPLC-QTOF-MS analysis.....	43
2.3.5 Bioassays	46
2.4 Results.....	47
2.4.1 HPLC analysis	47
2.4.2 UHPLC-QTOF-MS analysis.....	58
2.4.3 Effects of representative samples for SO, SP and SG on inflammatory mediators	80
2.5 Discussion	86
2.6 Conclusions.....	88
CHAPTER 3 HS EXERTES ANTI-ARTHRITIC EFFECTS AND INHIBITS THE TLR4 SIGNALING PATHWAY IN CIA RATS	89
3.1 Abstract.....	89
3.2 Introduction.....	91
3.3 Materials and methods	92
3.3.1 Chemical and reagents.....	92
3.3.2. Herbal materials	92
3.3.3 Preparation of HS.....	93
3.3.4 HPLC analysis of HS.....	94
3.3.5 Induction of CIA	95
3.3.6 Animal treatment	95
3.3.7 Macroscopic scoring of CIA.....	96
3.3.8 Radiographic analysis	96
3.3.9 Changes in body weight and food intake.....	97
3.3.10 Determination of IL-1 β , IL-6, TNF- α and MCP-1 in sera.....	97
3.3.11 Western blot analyses	97

3.3.12 Statistical analysis.....	98
3.4 Results.....	98
3.4.1 Quality control of HS.....	98
3.4.2 HS improved clinical arthritic conditions in CIA rats	100
3.4.3 HS improved food intake and reduced weight loss in CIA rats.....	102
3.4.4 HS attenuated the radiographic damage of CIA rats	104
3.4.5 HS decreased the secretion of inflammatory mediators regulated by transcription in TLR4 signaling pathway	106
3.4.6 HS inhibited TLR4 signaling in CIA rats	108
3.5 Discussion.....	110
3.6 Conclusion	111
CHAPTER 4 HS INHIBITS THE PRODUCTION OF INFLAMMATORY MEDIATORS REGULATED BY AP-1, NF-KB AND IRF3 IN LIPOPOLYSACCHARIDE-STIMULATED RAW 264.7 CELLS	112
4.1 Abstract.....	112
4.2 Introduction.....	114
4.3 Materials and methods	114
4.3.1 Reagents and materials	114
4.3.2. Herbal materials	115
4.3.3 Cell culture.....	116
4.3.4 Cell viability assay	116
4.3.5 Enzyme-linked immunosorbent assay (ELISA)	117
4.3.6. NO production measurement	117
4.3.7. Real-time polymerase chain reaction analysis.....	117
4.3.8. Western blotting.....	119
4.3.9 Extraction of cytoplasmic and nuclear proteins.....	119

4.3.10 Immunofluorescence staining	120
4.3.11 Detection of LPS binding on cell surface	120
4.3.12 Detection of TLR4-MD2 complex on cell surface	121
4.3.13 Statistical analysis.....	121
4.4 Results and discussion	121
4.4.1 HS decreased NO production in LPS-stimulated RAW264.7 cells..	121
4.4.2 HS decreased the production of pro-inflammatory mediators regulated by NF- κ B	123
4.4.3 HS inhibited NF- κ B p65 phosphorylation and reduced nuclear levels of p65 and p50 in LPS-stimulated RAW264.7 cells	126
4.4.4 HS inhibited phosphorylation of I κ B α and IKK α/β in LPS-stimulated RAW264.7 cells.....	130
4.4.5 HS inhibited production of MCP-1 and MIP-1 α in LPS-stimulated RAW264.7 cells.....	132
4.4.6 HS decreased the phosphorylation and nuclear levels of c-Jun and c-Fos in LPS-stimulated RAW264.7 cells.....	133
4.4.7 HS inhibited the phosphorylation of MAPKs in LPS-stimulated RAW264.7 cells.....	137
4.4.8 HS inhibited the phosphorylation of PI3K and Akt in LPS-stimulated RAW264.7 cells.....	140
4.4.9 HS inhibited the degradation of IRAK4 and IRAK1 in LPS-stimulated RAW264.7 cells.....	142
4.4.10 HS lowered protein levels of TRAF6 and phospho-TAK1 in LPS-stimulated RAW264.7 cells.....	144

4.4.11 HS inhibited the production of Rantes, the phosphorylation and nuclear level of IRF3 in LPS-stimulated RAW264.7 cells.....	146
4.4.12 HS down-regulated protein levels of TRAF3 and phospho-TBK1 in LPS-stimulated RAW264.7 cells.....	150
4.4.13 HS lowered mRNA levels of pro-inflammatory mediators regulated by NF- κ B, AP-1 and IRF3	152
4.4.14 HS inhibited NO production and lowered mRNA levels of cytokines/chmokines in RAW 264.7 cells treated with MPLAs	154
4.4.15 LPS diminished the effects of HS on the phosphorylation of three transcription factors in the TLR4 pathways.....	157
4.4.16 HS inhibited the interaction between LPS and TLR4.....	161
4.5 Conclusion	164
CHAPTER 5 IDENTIFICATION OF CHEMICAL COMPONENTS IN HS RESPONSIBLE FOR INHIBITING LPS BINDING TO TLR4-MD2.....	166
5.1 Abstract.....	166
5.2 Introduction.....	168
5.3 Materials and methods	169
5.3.1 Reagents and materials	169
5.3.2 Herbal preparation	169
5.3.3 UHPLC-QTOF-MS analysis.....	169
5.3.4 Target Preparation and Validation of Docking Method	171
5.4 Results and Discussion	172
5.4.1 UHPLC-QTOF-MS analysis.....	172
5.4.2 Molecular Docking Analyses of the identified chemical constituents	187

5.4.3 Ursolic acid (URA) inhibited NO production in LPS-stimulated RAW 264.7 cells.....	192
5.4.4 URA inhibited the interaction between LPS and TLR4	194
5.4.5 Determination of the 3D structure of the TLR4-MD2-URA complex.....	197
5.4.6 Confirmation of the binding site of URA with TLR4-MD2.....	200
5.4.7 Analysis of the inhibition mechanism of URA to TLR4-MD2	203
5.5 Conclusion	205
CHAPTER 6 SUMMARIES, GENERAL DISCUSSION, CONCLUSION AND PROSPECTS OF THE RESEARCH.....	206
6.1 Summaries	206
6.2 General discussion and conclusion	208
6.3 Future plans.....	209
6.3.1 Metabolic analyses.....	209
6.3.2 Network pharmacology analyses	209
REFERENCES	210
PUBLICATIONS.....	228
CURRICULUM VITAE.....	229